Published in Blood Weekly, October 10th, 2002
The new patent, which is part of a family of several U.S. patents that were previously issued, significantly expands the scope of protection available to Sangart's products including its lead oxygen transport agent, Hemospan. The entire family of patents is licensed to Sangart on an exclusive world-wide basis.
"This patent further strengthens our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.